Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
7.34
-0.03 (-0.41%)
At close: Dec 20, 2024, 4:00 PM
7.39
+0.05 (0.68%)
After-hours: Dec 20, 2024, 6:39 PM EST
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Vir Biotechnology stock have an average target of 36.4, with a low estimate of 12 and a high estimate of 110. The average target predicts an increase of 395.91% from the current stock price of 7.34.
Analyst Consensus: Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for VIR stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,398.64% | Nov 20, 2024 |
| Needham | Needham | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +158.86% | Nov 20, 2024 |
| Barclays | Barclays | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +254.22% | Nov 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,398.64% | Nov 4, 2024 |
| Needham | Needham | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +158.86% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
75.93M
from 86.18M
Decreased by -11.89%
Revenue Next Year
30.66M
from 75.93M
Decreased by -59.62%
EPS This Year
-3.97
from -4.59
EPS Next Year
-3.85
from -3.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 121.8M | 111.5M | 95.1M | |||
| Avg | 75.9M | 30.7M | 38.3M | |||
| Low | 60.6M | n/a | 4.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 41.3% | 46.9% | 210.3% | |||
| Avg | -11.9% | -59.6% | 24.9% | |||
| Low | -29.7% | - | -84.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.89 | -2.89 | -3.21 | |||
| Avg | -3.97 | -3.85 | -3.87 | |||
| Low | -3.94 | -5.17 | -5.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.